Skip to Main content Skip to Navigation
Journal articles

``Wnt/beta-Catenin in GIST''-Letter

Abstract : In an article published on September, 2017, in Molecular Cancer Therapeutics, Zeng and colleagues showed that the WNT/beta-catenin oncogenic pathway was activated in a subset of human gastrointestinal stromal tumors (GIST) and that inhibiting its signaling alone or in combination with imatinib has antitumor efficacy in vitro and in vivo in imatinib-sensitive and resistant preclinical models. However, they concluded that ``more investigation is needed to correlate beta-catenin activation with clinicopathologic features in GIST clinical samples.'' Here, we examined the activation score of the beta-catenin pathway in 160 clinically annotated clinical samples of operated primary GISTs. We showed that the beta-catenin activation score, assessed as continuous variable, was heterogeneous across samples. Higher score was associated with certain prognostic clinicopathologic characteristics, including mutational status, tumor size, and AFIP classification, and even more importantly, with more postoperative relapses in uni-and multivariate analyses. Such unfavorable independent prognostic value of beta-catenin activation reinforces the potential therapeutic value of this new target in GIST and nicely complements Zeng's study. (C) 2018 AACR.
Document type :
Journal articles
Complete list of metadata
Contributor : Ghislain Bidaut Connect in order to contact the contributor
Submitted on : Wednesday, May 29, 2019 - 2:50:38 PM
Last modification on : Tuesday, March 29, 2022 - 6:20:04 PM




Francois Bertucci, Pascal Finetti, Alexandre de Nonneville, Daniel Birnbaum. ``Wnt/beta-Catenin in GIST''-Letter. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (1), pp.327-328. ⟨10.1158/1535-7163.MCT-17-0948⟩. ⟨hal-02143618⟩



Record views